Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential

Group 1 - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is recognized as a top performer, with a remarkable increase of 629.64 percent in 2025, driven by positive clinical trial results for its therapy candidate targeting chronic myeloid leukemia (CML) [1][2] - The therapy candidate, TERN-701, demonstrated a 64 percent improvement in the conditions of 63 enrolled CML patients after 24 weeks of treatment [1][2] - A major molecular response rate of 74 percent was observed at a higher dosage of 320 mg among the trial participants [2] Group 2 - Terns Pharmaceuticals successfully raised $747.5 million through the issuance of over 18.68 million shares to the public, with funds allocated for the development and commercial launch of TERN-701 [2] - The remaining proceeds from the fundraising will be utilized for working capital and other general corporate purposes [2]